20 articles
Real-world study of 664 patients reveals effective treatment options after T-DXd discontinuation, with low lung disease recurrence rates.
Phase 2 trial explores whether combining oncolytic virus therapy with immunotherapy can rescue patients whose melanoma progressed on PD-1 blockade.
Spatial-EV-seq charts where cancer-shielding vesicles cluster in tissue, exposing why immunotherapy fails in some tumor zones.
Engineered immune cells target CD19+ cancer cells in patients with treatment-resistant lymphoma and leukemia.
Scientists modified patients' immune cells to better recognize and attack cancer tumors expressing NY-ESO-1 protein.
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
A new 'induce-target-kill' strategy uses TROP2-directed ADCs to eliminate drug-tolerant persister cells in EGFR-mutant lung cancer.
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
Genetically modified immune cells target blood cancer that stopped responding to standard treatments in 28-patient trial.
Small trial tests innovative immune cell therapy for patients with relapsed non-Hodgkin's lymphoma who failed standard treatments.
Researchers modified children's own immune cells to fight B-cell leukemia and lymphoma when standard treatments failed.
Combining CD38 and PD-1 inhibitors produced durable remissions in relapsed NK/T-cell lymphoma, with median response duration exceeding 29 months.
Scientists identify a mitochondria-proteasome-haem pathway that silences immune cells — and show bortezomib can fix it in CAR-T therapy.
Phase 1 data from 15 heavily pretreated Japanese myeloma patients confirms talquetamab's safety and efficacy, matching global trial results.
Key biotech companies developing T cell engager therapies that redirect immune cells to fight cancer more effectively.
A first-in-human trial shows CAR-modified stem cell memory T cells outperform standard CAR T cells in expansion, persistence, and complete responses.
Autologous NK cell therapy combined with immunotherapy tested in 27 patients with treatment-resistant cancers.
MD Anderson's Phase 1/2 trial explored injecting rituximab directly into spinal fluid to target CNS lymphoid malignancies.
Japanese trial shows dual HER2 blockade with pertuzumab plus trastuzumab improves overall survival even after prior pertuzumab treatment.
